News | November 07, 2012

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

Minimal progression of late lumen loss through 18 months

MiStent Micell Technologies Stents Bioresorbable Clinical Trial Study

November 7, 2012 — Micell Technologies Inc. announced positive data from two clinical studies of its investigational MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release. Eighteen-month outcomes from the DESSOLVE I trial, and nine-month data supporting all study endpoints in the DESSOLVE II trial, were presented by David Kandzari, M.D., director of interventional cardiology and chief scientific officer for the Piedmont Heart Institute of Atlanta, Ga., at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Based on the cumulative findings and pending regulatory approval, Micell anticipates that MiStent SES may provide an innovative treatment option with an impressive safety profile for patients suffering from coronary artery disease.

"MiStent has demonstrated excellent results as well as treatment advantages we have not seen in other drug-eluting stents. Achieving minimal progression of late lumen loss from four- through 18-month assessments is unique and a significant positive clinical outcome. Once MiStent is available to physicians, this novel product will also present interventional cardiologists with a meaningful and important alternative in addressing the limitations of permanent polymer DES products. Indeed, MiStent's performance characteristics and clinical data can serve as a foundation for the improvement of patient care," said Kandzari.

Data presentations at TCT included the following:

Eighteen Month Clinical and Imaging Results from the DESSOLVE I First-in-Human Trial of the MiStent SES with Absorbable Polymer: MiStent SES mean in-stent late lumen loss (LLL) was essentially unchanged through 18 months post-procedure in patients with discrete novo lesions in native coronary arteries. Initial angiographic evaluations on 25 subjects had a mean in-stent late LLL of 0.07 mm. The mean 18-month LLL for the same 25 subjects was essentially unchanged at 0.09 mm. Intravascular ultrasound (IVUS) confirmed minimal change in neointimal hyperplasia in the long-term follow-up with an initial mean (± standard deviation) percent obstruction of 7.2±4.8 percent and 11.2±8.1 percent at 18 months. The major adverse cardiac events (MACE) rate at 18 months was unchanged from 12 months, with only one non-target vessel non-Q-wave myocardial infarction (MI).

Nine Month Imaging and Twelve Month Clinical Results from the DESSOLVE II Randomized Trial of the MiStent SES with Absorbable Polymer: MiStent SES demonstrated statistically superior performance as compared to the Endeavor Sprint DES for the primary endpoint of in-stent LLL. At nine months' follow-up, in-stent LLL was 0.27 mm with a target lesion revascularization (TLR) rate of 0.9 percent. The MACE rates were 4.3 percent for MiStent SES and 6.7 percent for Endeavor.

"DESSOLVE II, a randomized controlled study, successfully met all endpoints. Patient evaluations at nine months confirmed that MiStent SES provided a healing profile comparable to that of a bare metal stent, with a median of only 0.3 percent uncovered stent struts, zero malapposition and a return of normal endothelial function with 100 percent of MiStent-treated vessels showing vasodilation. DESSOLVE II builds on the results of the first-in-human DESSOLVE I study, in which there was no increase in LLL through 18 months post-procedure," said Dennis J. Donohoe, M.D., Micell's chief medical advisor. "Each aspect of the MiStent SES was considered when designing a next-generation stent intended to deliver the efficacy of a drug-eluting stent with the safety profile of a bare metal stent. MiStent SES has the potential to address a pressing need to improve patient safety without sacrificing efficacy."

For more information:

Related Content

Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable| March 21, 2017 | Dave Fornell
March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of Cardiolo
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Absorb, bioresorbable stent, BVS, top cardiology story of 2016

The FDA clearance of the first fully bioresorbable stent, the Abbott Absorb BVS, was by far the top story of 2016. Readers clearly had a massive interest in this technology based on their page views of this article, related bioresorbable stent content and a video interviews with key ABSORB study investigators.

Feature | December 21, 2016 | Dave Fornell
The Diagnostic and Interventional Cardiology (DAIC) website had a record year in 2016, breaking 1 million pa
Videos | Stents Bioresorbable| November 09, 2016
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirb
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Fortitude bioresorbable stent

The Fortitude sirolimus-eluting bioresorbable stent.


News | Stents Bioresorbable| November 07, 2016
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C...
Overlay Init